AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30544411 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 50 μg (group F)
Number of subjects: 46
Study 27166238 — intervention group
Group type: EXPERIMENTAL
Intervention: JZP-110 150 mg/day weeks 1-4 and 300 mg/day weeks 5-12
Number of subjects: 93
Study 27166238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 25708712 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based training (3 days/week for 12 weeks)
Number of subjects: 36
Study 25708712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 23715565 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese men (BMI ≥ 30 kg/m²)
Number of subjects: 1931
Study 23715565 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight men (BMI 18.5 to 24.9 kg/m²)
Number of subjects: 1931
Study 23715565 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (all BMI categories)
Number of subjects: 1931
Study 21265309 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute dental trauma lecture
Number of subjects: 336
Study 21265309 — intervention group
Group type: COMPARATOR
Intervention: Control group (structured questionnaire)
Number of subjects: 336
Study 19057854 — intervention group
Group type: EXPERIMENTAL
Intervention: rhu EPO, 500u per kg, per week, 2 times weekly, subcutaneous
Number of subjects: 40
Study 16176313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia with mivacurium (0.2 mg.kg(‐1))
Number of subjects: 60
Study 16176313 — intervention group
Group type: COMPARATOR
Intervention: Propofol anesthesia with mivacurium (0.2 mg.kg(‐1))
Number of subjects: 60
Study 12952091 — intervention group
Group type: EXPERIMENTAL
Intervention: New discriminant combining parameters from a non-Rayleigh statistic model of backscattered envelope.
Number of subjects: 99
Study 12952091 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parameters with level of suspicion (LOS) scores of a radiologist.
Number of subjects: 99
Study 10489111 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 48
Study 10489111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9063758 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg
Number of subjects: 100
Study 9063758 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg
Number of subjects: 100
Study 9063758 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg
Number of subjects: 100
Study 9063758 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 25 mg
Number of subjects: 100
Study 9063758 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 50 mg
Number of subjects: 100
Study 9063758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1845806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Polio Vaccine (OPV)
Number of subjects: 0
Study 1845806 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced-Potency Inactivated Polio Vaccine (E-IPV)
Number of subjects: 0
Study 6338689 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Number of subjects: 13
Study 6338689 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.375 mg
Number of subjects: 13
Study 6338689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6338689 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 13
Study 30394672 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation (ARP) with a d‐PTFE membrane and freeze‐dried irradiated allogenic bone
Number of subjects: 34
Study 30394672 — intervention group
Group type: COMPARATOR
Intervention: Natural socket healing (control)
Number of subjects: 34
Study 29367425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 7863
Study 29367425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7863
Study 26901301 — intervention group
Group type: EXPERIMENTAL
Intervention: VISTA technique using Bio‐Gide membrane enhanced with GEM 21S
Number of subjects: 15
Study 26901301 — intervention group
Group type: COMPARATOR
Intervention: Periosteal pedicle graft (PPG)
Number of subjects: 15
Study 24492159 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel patient counseling program
Number of subjects: 14
Study 24492159 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study 22947589 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU weekly for 8 weeks
Number of subjects: 151
Study 22947589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 20566398 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Food First (TFF)
Number of subjects: 57
Study 20566398 — intervention group
Group type: COMPARATOR
Intervention: Test Food Last (TFL)
Number of subjects: 57
Study 17662632 — intervention group
Group type: EXPERIMENTAL
Intervention: Homocysteine (Hcy)
Number of subjects: 184
Study 17662632 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 184
Study 17662632 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 184
Study 17662632 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin
Number of subjects: 184
Study 17662632 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid
Number of subjects: 184
Study 17662632 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose
Number of subjects: 184
Study 15124669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AraC during induction therapy
Number of subjects: 938
Study 15124669 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose AraC during induction therapy
Number of subjects: 938
Study 15124669 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF priming
Number of subjects: 938
Study 15124669 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF priming
Number of subjects: 938
Study 15124669 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 938
Study 15124669 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 938
Study 11236040 — intervention group
Group type: EXPERIMENTAL
Intervention: NebuChamber
Number of subjects: 141
Study 11236040 — intervention group
Group type: COMPARATOR
Intervention: Babyhaler
Number of subjects: 141
Study 9714355 — intervention group
Group type: EXPERIMENTAL
Intervention: TH and rifampicin (TH+R)
Number of subjects: 82
Study 9714355 — intervention group
Group type: COMPARATOR
Intervention: TH alone
Number of subjects: 82
Study 9714355 — intervention group
Group type: EXPERIMENTAL
Intervention: TH and methotrexate (TH+M)
Number of subjects: 82
Study 9714355 — intervention group
Group type: EXPERIMENTAL
Intervention: TH+R
Number of subjects: 82
Study 7913644 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol (3 mg/ml)
Number of subjects: 40
Study 7913644 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2.5 mg/ml)
Number of subjects: 40
Study 7913644 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2.5 mg/ml) and Metipranolol (3 mg/ml)
Number of subjects: 40
Study 2726319 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched groups
Number of subjects: 28
Study 2726319 — intervention group
Group type: COMPARATOR
Intervention: Non-protein-enriched groups
Number of subjects: 28
Study 1177789 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN retard (slow-release isosorbide dinitrate)
Number of subjects: 20
Study 1177789 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 31545048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med)
Number of subjects: 10
Study 31545048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast food diet (FF)
Number of subjects: 10
Study 31545048 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-associated proteins including ApoE
Number of subjects: 10
Study 31545048 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL functional capacity
Number of subjects: 10
Study 29037635 — intervention group
Group type: EXPERIMENTAL
Intervention: Talocrural joint manipulation (TCJM)
Number of subjects: 40
Study 29037635 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 40
Study 25991421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-storage filtration (group 1, n=53)
Number of subjects: 106
Study 25991421 — intervention group
Group type: COMPARATOR
Intervention: Bedside filtration (group 2, n=53)
Number of subjects: 106
Study 23269401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (VyproII(®), TiMesh(®))
Number of subjects: 59
Study 23269401 — intervention group
Group type: COMPARATOR
Intervention: Standard polypropylene (Marlex(®))
Number of subjects: 59
Study 23200592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction coil treatment (LVRC)
Number of subjects: 100
Study 23200592 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 100
Study 19188101 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyThink program (4 sessions of 50 minutes each)
Number of subjects: 277
Study 19188101 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual classes)
Number of subjects: 277
Study 17425783 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (750 mg infusion)
Number of subjects: 80
Study 17425783 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaccines on day 1 only)
Number of subjects: 80
Study 15383785 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh repair
Number of subjects: 181
Study 15383785 — intervention group
Group type: COMPARATOR
Intervention: Suture repair
Number of subjects: 181
Study 11242721 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced feedback intervention (EFI)
Number of subjects: 29
Study 11242721 — intervention group
Group type: COMPARATOR
Intervention: Written feedback intervention (WFI)
Number of subjects: 29
Study 9500570 — intervention group
Group type: EXPERIMENTAL
Intervention: acute hyperglycemic hyperinsulinemia (HG) with plasma glucose at 15 mmol/L
Number of subjects: 6
Study 9500570 — intervention group
Group type: EXPERIMENTAL
Intervention: euglycemic hyperinsulinemia (HI) with plasma insulin at 80 mU/L and glucose at 4 to 5 mmol/L
Number of subjects: 6
Study 9500570 — intervention group
Group type: COMPARATOR
Intervention: intravenous (i.v.) saline (control)
Number of subjects: 6
Study 7884300 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP (both global and bridging)
Number of subjects: 51
Study 7884300 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 51
Study 7884300 — intervention group
Group type: EXPERIMENTAL
Intervention: Global or bridging part of PREP
Number of subjects: 51
Study 1697950 — intervention group
Group type: COMPARATOR
Intervention: Absent rate response (VVI in the Sensolog group)
Number of subjects: 20
Study 1697950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyporesponsive (DDD in the dual chamber group)
Number of subjects: 20
Study 1697950 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate response (VVIR, DDDR according to Manufacturer's instructions)
Number of subjects: 20
Study 1697950 — intervention group
Group type: EXPERIMENTAL
Intervention: Over responsive (VVIR+, DDDR+)
Number of subjects: 20
Study 1697950 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 343509 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline ethylenediamine, 400 mg orally
Number of subjects: 0
Study 343509 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide, 5 mg orally
Number of subjects: 0
Study 31315940 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT+MICT
Number of subjects: 82
Study 31315940 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 82
Study 30740955 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LS)
Number of subjects: 801
Study 30740955 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (LT)
Number of subjects: 801
Study 28828489 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC
Number of subjects: 188
Study 28828489 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-FTC
Number of subjects: 188
Study 28828489 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC-TDF
Number of subjects: 188
Study 28828489 — intervention group
Group type: COMPARATOR
Intervention: TDF-FTC
Number of subjects: 188
Study 28828489 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 188
Study 25759235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (CR) intervention
Number of subjects: 48
Study 25759235 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL) control condition
Number of subjects: 48
Study 24582466 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence exercises
Number of subjects: 156
Study 24582466 — intervention group
Group type: COMPARATOR
Intervention: Encouraged control group
Number of subjects: 156
Study 24582466 — intervention group
Group type: EXPERIMENTAL
Intervention: Accommodation exercises
Number of subjects: 156
Study 24582466 — intervention group
Group type: COMPARATOR
Intervention: Other treatment groups
Number of subjects: 156
Study 22430457 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts in BMI category (e.g., overweight to healthy weight)
Number of subjects: 3993
Study 22430457 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifts in BMI category (e.g., healthy weight to overweight)
Number of subjects: 3993
Study 22430457 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in BMI category
Number of subjects: 3993
Study 22430457 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases in BMI category
Number of subjects: 3993
Study 22430457 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys who increased BMI category
Number of subjects: 3993
Study 19915236 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic circumcision
Number of subjects: 20
Study 19915236 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncircumcised males)
Number of subjects: 20
Study 17690923 — intervention group
Group type: EXPERIMENTAL
Intervention: P-teeth group (periosteum contacting the tooth surface)
Number of subjects: 8
Study 17690923 — intervention group
Group type: EXPERIMENTAL
Intervention: P-flap group (periosteum contacting the flap)
Number of subjects: 8
Study 15101293 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 2226
Study 15101293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2226
Study 11712773 — intervention group
Group type: EXPERIMENTAL
Intervention: INVEST (treatment for 12 months)
Number of subjects: 81649
Study 9613267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.125 mg
Number of subjects: 80
Study 9613267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.25 mg
Number of subjects: 80
Study 9613267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 0.375 mg
Number of subjects: 80
Study 9613267 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 80
Study 7815243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10-12 mg/kg/day)
Number of subjects: 51
Study 7815243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid with taurine (18-22 mg/kg/day)
Number of subjects: 51
Study 7815243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 7815243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 51
Study 1662233 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/kg IVIG (Gammagard)
Number of subjects: 31
Study 1662233 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/kg IVIG (Gammagard)
Number of subjects: 31
Study 373921 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 2 mg/ml injected IV 1 hour before cytostatic treatment and again 4 hours later
Number of subjects: 41
Study 373921 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected IV 1 hour before cytostatic treatment and again 4 hours later
Number of subjects: 41
Study 373921 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 2 mg/ml
Number of subjects: 41
Study 373921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31319102 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 81
Study 31319102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation intervention
Number of subjects: 81
Study 31319102 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control
Number of subjects: 81
Study 28490230 — intervention group
Group type: EXPERIMENTAL
Intervention: In utero hematopoietic cell transplantation (IUHCT)
Number of subjects: 79
Study 26032934 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical peeling combined with physical effect (4% AHA solution)
Number of subjects: 23
Study 26032934 — intervention group
Group type: COMPARATOR
Intervention: Chemical peeling alone (control group)
Number of subjects: 23
Study 24144073 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 1079
Study 22277458 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dabigatran
Number of subjects: 0
Study 22277458 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dabigatran
Number of subjects: 0
Study 22277458 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran (both doses)
Number of subjects: 0
Study 22277458 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 0
Study 22277458 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 18687056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 20
Study 18687056 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 20
Study 16891861 — intervention group
Group type: EXPERIMENTAL
Intervention: peptides + Montanide ISA‐51
Number of subjects: 25
Study 16891861 — intervention group
Group type: EXPERIMENTAL
Intervention: peptides + Montanide ISA‐51 + GM‐CSF (10 microg)
Number of subjects: 25
Study 16891861 — intervention group
Group type: EXPERIMENTAL
Intervention: peptides + Montanide ISA‐51 + GM‐CSF (50 microg)
Number of subjects: 25
Study 16891861 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 25
Study 16988082 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention (2000 additional steps/day and 2 servings/day of ready-to-eat cereal for 13 weeks)
Number of subjects: 105
Study 16988082 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided)
Number of subjects: 105
Study 14698782 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]‐meta‐hydroxyephedrine for pre-synaptic function
Number of subjects: 28
Study 14698782 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]‐CGP12177 for post-synaptic function
Number of subjects: 28
Study 14698782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-synaptic function
Number of subjects: 28
Study 10569322 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 686
Study 10569322 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 686
Study 10569322 — intervention group
Group type: EXPERIMENTAL
Intervention: ambulatory ischemia monitoring
Number of subjects: 686
Study 10569322 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise testing
Number of subjects: 686
Study 10569322 — intervention group
Group type: COMPARATOR
Intervention: treatment effects on ambulatory ischemia
Number of subjects: 686
Study 10569322 — intervention group
Group type: EXPERIMENTAL
Intervention: ventricular premature complexes
Number of subjects: 686
Study 8912401 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 107
Study 8912401 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 107
Study 1860640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 21
Study 1860640 — intervention group
Group type: COMPARATOR
Intervention: No operation (Control)
Number of subjects: 21
Study 6349651 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate sodium (300 mg per day for 6 weeks)
Number of subjects: 40
Study 6349651 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (500 mg per day for 1 week and 300 mg per day for 5 weeks)
Number of subjects: 40
Study 6349651 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg per day for 6 weeks)
Number of subjects: 40
Study 6349651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys who perpetrated sexual IPV
Number of subjects: 2199
Study 29444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys' attitudes toward perpetrating sexual IPV
Number of subjects: 2199
Study 29444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys' perception of social network influence
Number of subjects: 2199
Study 29444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys' self-efficacy to refrain from pressuring
Number of subjects: 2199
Study 29444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetrators vs. nonperpetrators
Number of subjects: 2199
Study 29444627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention not to perpetrate sexual IPV
Number of subjects: 2199
Study 31943761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - antenatal/postnatal intervention with proactive telephone support and written materials
Number of subjects: 400
Study 31943761 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG) - received active control intervention
Number of subjects: 400
Study 31943761 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Group (SCG) - received standard care
Number of subjects: 400
Study 29388845 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive Advanced
Number of subjects: 20
Study 29388845 — intervention group
Group type: EXPERIMENTAL
Intervention: Optive
Number of subjects: 20
Study 29388845 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20